Medium-dose intravenous methylprednisolone pulse therapy for thyroid-associated orbitopathy.
Clinical activity score fell after steroid pulse therapy in thyroid eye disease
Medium-dose intravenous methylprednisolone pulse therapy for thyroid-associated orbitopathy.
To evaluate the efficacy and safety of a medium-dose intravenous methylprednisolone (intravenous methylprednisolone) pulse regimen for moderate-to-severe active thyroid-associated orbitopathy (thyroid-associated orbitopathy), with change in clinical activity score (clinical activity score) as the primary outcome.
With active moderate-to-severe thyroid-associated orbitopathy (clinical activity score≥3) received intravenous methylprednisolone totaling 4.0 g (500 mg daily for 3 consecutive days, followed by 500 mg every 3wk for 5 cycles).
clinical activity score dropped, showing much less active eye disease
The mean age of the participants was 38.63±12.11y, and 19 (63.3%) were male.
The mean degree of proptosis decreased from 22.47±1.59 to 20.13±1.97 mm (-2.34±1.25 mm; P <0.0001).
BCVA improved from 0.46±0.31 to 0.15±0.18 logMAR (-0.31±0.28; P =0.02).
The mean IOP decreased from 16.80±3.56 to 14.93±1.73 mm Hg (-1.87±2.45 mm Hg; P <0.001).
Medium-dose intravenous methylprednisolone (4.0 g) significantly improve disease activity, proptosis, visual acuity, and IOP, with an acceptable safety profile.
This regimen represents an effective and safer alternative to high-dose intravenous methylprednisolone for active moderate-to-severe thyroid-associated orbitopathy, particularly in resource-limited settings.
Larger, multicenter trials with longer follow-up periods are needed to confirm these findings.